08:03 AM EST, 11/06/2024 (MT Newswires) -- Charles River Laboratories International ( CRL ) reported Q3 non-GAAP earnings Wednesday of $2.59 per diluted share, down from $2.72 a year earlier.

Analysts polled by Capital IQ expected $2.42.

Revenue for the quarter ended Sept. 28 was $1.01 billion, down from $1.03 billion a year earlier.

Analysts surveyed by Capital IQ expected $975.5 million.

For 2024, the biopharmaceutical services provider raised its non-GAAP EPS estimate to $10.10 to $10.30 on a 2% to 3% decline in revenue, from $9.90 to $10.20 on a 2.5% to 4.5% revenue decline. Analysts polled by Capital IQ expect normalized EPS of $10.00 on $3.99 billion in revenue.

Charles River shares gained more than 6% in premarket trading.

Price: 184.01, Change: +1.89, Percent Change: +1.04